Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Targeting DPP-4

Targeting DPP-4

Company Product Status
Novartis Galvus vildagliptin (LAF237)

Read the full 98 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE